naloxagol

Details

Key Milestones2
Call for patient/clinician/industry input open 21-Nov-24
Call for patient/clinician/industry input closed 17-Jan-25
Submission receivedNovember 22, 2024
Expert committee meeting (initial)May 15, 2025

nivolumab

Details

Key Milestones2
Call for patient/clinician/industry input open 21-Nov-24
Call for patient/clinician/industry input closed 17-Jan-25
Submission receivedNovember 27, 2024
Expert committee meeting (initial)May 15, 2025

fidaxomicin

Details

Key Milestones2
Call for patient/clinician/industry input open 21-Nov-24
Call for patient/clinician/industry input closed 17-Jan-25
Submission receivedNovember 22, 2024
Expert committee meeting (initial)May 15, 2025

nemolizumab

Details

Key Milestones2
Call for patient/clinician input openNovember 21, 2024
Call for patient/clinician input closedJanuary 17, 2025
Submission receivedJanuary 07, 2025
Submission acceptedJanuary 21, 2025
Review initiatedJanuary 22, 2025
Draft CADTH review report(s) provided to sponsor for commentApril 09, 2025
Deadline for sponsors commentsApril 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorMay 15, 2025
Expert committee meeting (initial)May 28, 2025
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedbackJune 19, 2025
End of feedback periodJuly 04, 2025

fecal microbiota

Details

Key Milestones2
Call for patient/clinician input open15-Nov-24
Call for patient/clinician input closed17-Jan-25
Submission received03-Jan-25
Submission accepted17-Jan-25
Review initiated20-Jan-25
Draft CADTH review report(s) provided to sponsor for comment11-Apr-25
Deadline for sponsors comments24-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-May-25
Expert committee meeting (initial)28-May-25
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedback19-Jun-25
End of feedback period04-Jul-25

dupilumab

Details

Key Milestones2
Call for patient/clinician input openNovember 12, 2024
Call for patient/clinician input closedJanuary 10, 2025
Submission receivedDecember 20, 2024
Submission acceptedJanuary 13, 2025
Review initiatedJanuary 14, 2025
Draft CADTH review report(s) provided to sponsor for commentApril 09, 2025
Deadline for sponsors commentsApril 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorMay 15, 2025
Expert committee meeting (initial)May 28, 2025
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedbackJune 19, 2025
End of feedback periodJuly 04, 2025

ribociclib

Details

Key Milestones2
Call for patient/clinician input open07-Nov-24
Call for patient/clinician input closed06-Jan-25
Submission received19-Dec-24
Submission accepted13-Jan-25
Clarification:

- Submission was not accepted for review on 10 January 2025

Review initiated14-Jan-25
Clarification:

- Submission temporarily suspended

- Additional information has been received and the temporary suspension of the review has been lifted

Draft CADTH review report(s) provided to sponsor for comment28-Apr-25
Deadline for sponsors comments07-May-25
CDA-AMC review report(s) and responses to comments provided to sponsor30-May-25
Expert committee meeting (initial)11-Jun-25
Draft recommendation issued to sponsorJune 23, 2025
To
June 25, 2025
Draft recommendation posted for stakeholder feedback03-Jul-25
End of feedback period17-Jul-25

dupilumab

Details

Key Milestones2
Call for patient/clinician input openNovember 07, 2024
Call for patient/clinician input closedJanuary 06, 2025
Submission receivedDecember 18, 2024
Submission acceptedJanuary 09, 2025
Review initiatedJanuary 10, 2025
Draft CADTH review report(s) provided to sponsor for commentApril 08, 2025
Deadline for sponsors commentsApril 17, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorMay 15, 2025
Expert committee meeting (initial)May 28, 2025
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedbackJune 19, 2025
End of feedback periodJuly 04, 2025